Overview

A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain

Status:
Completed
Trial end date:
1999-08-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study was to characterize the steady-state pharmacokinetic (metabolism and action) profile of OROS hydromorphone HCI (slow release) in patients who required opioid therapy on a daily basis for chronic pain conditions. Patients stabilized on prior opioids were converted to OROS hydromorphone slow release and titrated (slowly increased or decreased) to adequate analgesia (pain relief). They were maintained at that dose for 4-10 days and had blood samples drawn over 24 hours on the last day of study.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Alza Corporation, DE, USA
Treatments:
Hydromorphone
Criteria
Inclusion Criteria:

- Patients who had chronic nonmalignant or chronic cancer pain and were currently
receiving strong oral or transdermal opioid analgesics (drug that relieves pain) on a
daily basis or patients suitable for advancement of therapy to step 3 on the WHO
(World Health Organization) analgesic (drug that relieves pain) ladder

- Patients who required the opioid equivalent of at least 32 mg but no more than 300 mg
of oral morphine sulfate or opioid equivalent (exclusive of breakthrough pain
medication) every 24 hours for the management of chronic nonmalignant or cancer pain

- Patients who were expected to have reasonably stable opioid requirements for the
duration of the study

Exclusion Criteria:

- Patients intolerant of or hypersensitive to hydromorphone (or other opioid drugs)

- Patients who were pregnant or breast-feeding.Patients with any dysphagia or unable to
swallow tablets, acute abdominal conditions that may be obscured by opioids or
gastrointestinal disorders, including pre-existing severe GI narrowing, that may
affect the absorption or transit of orally administered drugs

- Patients with any significant CNS disorder, including but not limited to head injury,
intracranial lesion, increased intracranial pressure, seizure disorder, stroke within
the past 6 months, and disorders of cognition, and clinically significant impaired
hematological function

- Patients that may be at risk for serious decreases in blood pressure following
administration of an opioid analgesic (pain relief)